Simplexvirus (HSV) Infections is an indication for drug development with over 70 pipeline drugs currently active. According to GlobalData, preregistered drugs for Simplexvirus (HSV) Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Simplexvirus (HSV) Infections compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Simplexvirus (HSV) Infections overview

Herpes simplex virus (HSV) infections, also known as simplexvirus infections, are caused by two types of viruses: HSV-1 and HSV-2. HSV-1 typically causes oral herpes, manifesting as cold sores around the mouth, while HSV-2 is primarily responsible for genital herpes. However, both types can cause infections in either location. These infections are highly contagious and transmitted through direct contact with an infected individual, especially during active outbreaks. The primary infection often occurs during childhood or adolescence, with the virus establishing lifelong latency in nerve cells after the initial outbreak. The virus may periodically reactivate, causing recurrent outbreaks, which are characterized by the appearance of sores, blisters, or ulcers in the affected area. Recurrences can be triggered by factors such as stress, illness, sun exposure, hormonal changes, or a weakened immune system. HSV infections can have emotional and psychological impacts due to the stigma associated with the condition. Seeking support from healthcare professionals and support groups can be beneficial in managing the psychological aspects of living with herpes. Regular monitoring and managing triggers can aid in reducing the frequency and severity of outbreaks, improving the quality of life for individuals affected by HSV infections.

For a complete picture of PTSR and LoA scores for drugs in Simplexvirus (HSV) Infections, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.